Ghayas C. Issa

Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Management of chronic myeloid leukemia in 2025

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial

Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

CML-754: Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis

Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) <i>KMT2Ar</i> Acute Leukemia

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Revumenib Monotherapy in Patients with Relapsed/Refractory <i>KMT2Ar</i> Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Revumenib Monotherapy in Patients with Relapsed/Refractory <i>KMT2Ar</i> Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)